Collegium Pharmaceutical
COLL
73 hedge funds and large institutions have $173M invested in Collegium Pharmaceutical in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 13 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
4% more funds holding
Funds holding: 70 → 73 (+3)
36% less capital invested
Capital invested by funds: $270M → $173M (-$96.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.44M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$2.28M |
| 4 |
HM
HealthCor Management
New York
|
+$1.65M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.89M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.83M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.16M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.31M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.56M |
COLL Hedge Fund Activity: Q2 2016 in Review
73 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2016, worth a combined $173M — down 36% from $270M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new COLL positions and 13 closed out — a net gain of 4 holders — while 32 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $8.89M sold.
- 73 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2016, up from 70 in Q1 2016.
- Funds reported $173M of Collegium Pharmaceutical stock for Q2 2016, down 36% quarter-over-quarter.
- 17 funds opened new Collegium Pharmaceutical positions in Q2 2016 and 13 closed out, a net change of +4 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2016 was Fidelity Investments, an estimated $4M added.
- The largest Collegium Pharmaceutical seller in Q2 2016 was Adage Capital Partners, an estimated $8.89M sold.
Based on aggregated 13F filings for Q2 2016.